F. Sirzén

发表

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

J. Blay, M. Hidalgo, J. Baselga, 2015, The New England journal of medicine.

A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine

C. Twelves, J. Cassidy, P. Hoff, 2009, Clinical pharmacology and therapeutics.

Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma.

B. Joseph, B. Zhivotovsky, R. Lewensohn, 1999, Biochemical and biophysical research communications.

Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients

E. Oki, M. Morita, Y. Kakeji, 2013, International Journal of Clinical Oncology.

Potential regional differences for the tolerability profiles of fluoropyrimidines.

E. Van Cutsem, J. Tabernero, J. Bertino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

W. Scheithauer, L. Saltz, S. Clarke, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

E. Van Cutsem, G. Lyman, H. Hurwitz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

W. Scheithauer, L. Saltz, S. Clarke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial.

Y. Bang, J. Ji, Y. W. Kim, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.

G. Hillerdal, K. Lamberg, S. Friesland, 2008, Anticancer research.

The kinetics and cytotoxicity of cisplatin and its monohydrated complex.

R. Lewensohn, J. Yachnin, F. Sirzén, 1998, Cancer letters.

Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies

P. Catalano, A. Benson, J. Cassidy, 2007 .

Reply to S. Hapani et al

G. Lyman, H. Hurwitz, U. Rohr, 2011 .

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).

J. Blay, M. Hidalgo, J. Baselga, 2014 .

Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax.

J. Bergh, B. Zhivotovsky, R. Lewensohn, 1998, Lung cancer.

A cytotoxic, apoptotic, low-molecular weight factor from pineal gland.

V. Mutt, T. Bergman, P. Biberfeld, 1999, Life sciences.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Y. Bang, J. Ji, Y. Mok, 2012, The Lancet.

A Systematic Overview of Radiation Therapy Effects in Non-Small Cell Lung Cancer

F. Sirzén, E. Cavallin-ståhl, E. Kjellén, 2003, Acta oncologica.

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

E. Van Cutsem, N. Harbeck, D. Miles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell cycle‐dependent regulation of the DNA‐dependent protein kinase

R. Lewensohn, A. Nilsson, F. Sirzén, 1999, Cell proliferation.

DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity.

B. Zhivotovsky, R. Lewensohn, A. Nilsson, 1999, European journal of cancer.

The role of radiotherapy in treatment of stage I non-small cell lung cancer.

I. Lax, R. Lewensohn, F. Sirzén, 2003, Lung cancer.

Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities.

J. Bergh, B. Zhivotovsky, R. Lewensohn, 1998, Anticancer research.

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, J. Tabernero, 2015 .

VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).

J. Blay, J. Baselga, I. Puzanov, 2014 .

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

J. Blay, J. Baselga, O. Abdel-Wahab, 2014 .